Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Texas Retina’s Melissa Alva Recognized as a Top Study Coordinator in Clinical Research for 2024
InFocus, an international provider of ophthalmology clinical research and development services, recently named Texas Retina Senior Clinical Research Coordinator Melissa Alva as a “Top Study Coordinator in Retina Clinical Research for 2024,”
read more
10 New Clinical Trials Available at Texas Retina
In the last two decades, medical researchers have made significant advances in the diagnosis and treatment of retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision.
read more
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read more
New Clinical Trials Available at Texas Retina
At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one
read more New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more
Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more Four New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read more
FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more